Search
See the whole debate « Previous speaker Next speaker »
Dr. Colm Henry:
The latest judgment of the drugs committee, by a narrow majority, was not to accept the drug based on cost-effectiveness. The matter will go to the HSE leadership in June.
No comments
Log in or join to post a public comment.
No comments